Stanford clinicians take their cue from sports and election predictions to calculate an "in-game probability" of success when treating cancer patients.
Stanford researchers develop a machine-learning computer model for mammography assessment in hopes of aiding radiologists’ clinical decisions.
Many metastatic colorectal cancers appear "born to be bad," spreading to other organs before any diagnosis has been made, say Stanford researchers.
A patient worried that cancer may run in her family finds answers through genetic testing offering by Stanford Medicine's Humanwide project.
A recent Stanford Medicine event, Celebrating Cancer Survivors, brought survivors together to share a variety of stories about living with cancer.
In this In the Spotlight Q&A, radiology instructor Ahmed Nagy El Kaffas shares how a best friend and a trip to China shaped his early career.
Stanford researchers find that colorectal cancer is being diagnosed at later stages in younger patients, suggesting risk of the disease is growing.
In this essay, which originally appeared in Months to Years, writer Nicole Hardina reflects on caregiving for her partner who was dying of brain cancer.
A radio show features a Stanford oncologist discussing ultra-fast "flash" radiation therapy, which may kill cancer cells with less collateral damage.
The prevalence of genetic testing in the United States falls short of the recommended guidelines for women with ovarian cancer, new research indicates.
Study finds that starting colorectal cancer screening at age 45 would avert deaths, but testing more older people would be more beneficial.
A push to personalize medicine can backfire when it comes to screening for colorectal cancer, says a Stanford gastroenterologist.
Editors note: The family has requested removing the video to protect their daughter's privacy. We apologize for the inconvenience.
Scientists have modified immune cells, imbuing them with the ability to not only detect, but reveal, the presence of a tumor.
Stanford researchers make progress in predicting which patients will suffer heart problems from chemotherapy, and may have found a drug to mitigate them.
Molecular data identifies breast cancer subgroups likely to recur decades after successful treatment, predicts probable timing and location of metastases.